Accessibility Menu
 
Editas Medicine logo

Editas Medicine

(NASDAQ) EDIT

Current Price$2.31
Market Cap$227.06M
Since IPO (2016)-87%
5 Year-94%
1 Year+78%
1 Month+23%

Editas Medicine Financials at a Glance

Market Cap

$227.06M

Revenue (TTM)

$40.52M

Net Income (TTM)

$160.06M

EPS (TTM)

$-1.88

P/E Ratio

-1.23

Dividend

$0.00

Beta (Volatility)

2.07 (High)

Price

$2.31

Volume

41,619

Open

$2.25

Previous Close

$2.32

Daily Range

$2.25 - $2.47

52-Week Range

$0.91 - $4.54

EDIT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Editas Medicine

Industry

Biotechnology

Employees

87

CEO

Gilmore O’Neill, MD

Headquarters

Cambridge, MA 02141, US

EDIT Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-4%

Net Income Margin

-4%

Return on Equity

-198%

Return on Capital

-1%

Return on Assets

-86%

Earnings Yield

-81.30%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$227.06M

Shares Outstanding

97.87M

Volume

41.62K

Short Interest

0.00%

Avg. Volume

1.77M

Financials (TTM)

Gross Profit

$40.52M

Operating Income

$99.34M

EBITDA

$148.61M

Operating Cash Flow

$165.24M

Capital Expenditure

$607.00K

Free Cash Flow

$165.85M

Cash & ST Invst.

$146.65M

Total Debt

$76.71M

Editas Medicine Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$24.74M

-19.2%

Gross Profit

$24.74M

-19.2%

Gross Margin

100.00%

N/A

Market Cap

$227.06M

N/A

Market Cap/Employee

$923.02K

N/A

Employees

246

N/A

Net Income

$5.62M

+87.6%

EBITDA

$5.28M

+84.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$69.94M

-70.2%

Accounts Receivable

$15.18M

-6.7%

Inventory

$0.00

N/A

Long Term Debt

$65.68M

+222.3%

Short Term Debt

$11.03M

-24.7%

Return on Assets

-85.81%

N/A

Return on Invested Capital

-1.19%

N/A

Free Cash Flow

$36.45M

+29.0%

Operating Cash Flow

$36.39M

+28.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VYGRVoyager Therapeutics, Inc.
$4.11+1.86%
CABACabaletta Bio, Inc.
$2.79+0.18%
PRQRProQR Therapeutics N.V.
$1.49-6.01%
KYTXKyverna Therapeutics, Inc.
$8.09+2.77%

Trending Stocks

Symbol / CompanyPricePrice Chg
EEIQEpicQuest Education Group International
$7.41+1.71%
TQQQProShares Trust - ProShares UltraPro Qqq
$41.68-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.84+0.07%
QQQInvesco QQQ Trust
$575.77-0.02%

Questions About EDIT

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.